1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | Vyepti |
| structure | File | |
| classes | List of String, delimiter: , | Anti-CGRP ligand monoclonal antibody |
| mechanism | String | Humanized IgG1 monoclonal antibody binding CGRP peptide; IV infusion enables fastest onset of any CGRP mAb |
| uses | String | Preventive treatment of migraine in adults |
| starting_dose | String | 100 mg IV every 3 months; may increase to 300 mg IV every 3 months |
| preparations | String | 100 mg/mL vial for IV infusion |
| fda_max | String | 300 mg/quarter |
| pill_id | Text | |
| routes | List of String, delimiter: , | Intravenous infusion |
| onset | String | Effect demonstrated within 24 hours in some patients |
| duration | String | 3-month dosing interval |
| halflife | String | ~27 days |
| bioavailability | String | 100% (IV) |
| pregnancy | String | Limited data; avoid |
| legal | String | Rx |
